Leukemia · 1999
A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Niehues T, Kapaun P, Harms D O, Burdach S, Kramm C, Körholz D, Janka-Schaub G, Göbel U
Аннотация
During T cell selection in the thymic cortex more than 90% of the thymocytes are eliminated by apoptosis. Based on this biology, we propose to define blasts of T cell acute lymphoblastic leukemia (ALL) with the phenotype of cortical thymocytes (CD1+ and/or CD4+ 8+) as selection-related (SR) and all other T-ALL immunophenotypes as non-selection-related (NSR). The COALL cooperative treatment studies for childhood ALL offer a tool to study the outcome in T-ALL subgroups as children with T-ALL are allocated uniformly to the high risk arm of the protocol. In the COALL-85, -89 and -92 protocols, 39/83 cases presented as SR and 44/83 cases as NSR. Five-year event-free survival of SR phenotype is significantly better compared to the NSR group (0.87 +/- 0.06 vs 0.66 +/- 0.07, log rank test, P = 0.01). T-ALL with SR phenotype is a distinct subgroup of leukemia with excellent prognosis under a high risk treatment protocol.
Предметные рубрики MeSH
AdolescentAntigens, CDAntigens, NeoplasmAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseCentral Nervous SystemChildChild, PreschoolClonal DeletionCombined Modality TherapyCranial IrradiationCyclophosphamideCytarabineDaunorubicinDexamethasoneDisease-Free SurvivalDoxorubicinFemaleFollow-Up StudiesGermanyHumansImmunophenotypingInfantLeukemia-Lymphoma, Adult T-CellLeukemic InfiltrationMaleMercaptopurineMethotrexateMulticenter Studies as TopicNeoplastic Stem CellsPrednisoloneRemission InductionRiskT-Lymphocyte SubsetsTeniposideThioguanineTreatment OutcomeVincristine